Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Participatory Medicine

Date Submitted: Jul 18, 2021
Open Peer Review Period: Jul 18, 2021 - Jul 27, 2021
Date Accepted: Oct 3, 2021
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Implementing the Co-Immune Open Innovation Program to Address Vaccination Hesitancy and Access to Vaccines: Retrospective Study

Masselot C, Greshake Tzovaras B, Graham C, Finnegan G, Jeyaram R, Vitali I, Landrain T, Santolini M

Implementing the Co-Immune Open Innovation Program to Address Vaccination Hesitancy and Access to Vaccines: Retrospective Study

J Particip Med 2022;14(1):e32125

DOI: 10.2196/32125

PMID: 35060917

PMCID: 8817221

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Co-Immune: a case study on open innovation for vaccination hesitancy and access

  • Camille Masselot; 
  • Bastian Greshake Tzovaras; 
  • Christopher Graham; 
  • Gary Finnegan; 
  • Rathin Jeyaram; 
  • Isabelle Vitali; 
  • Thomas Landrain; 
  • Marc Santolini

ABSTRACT

Background:

The rise of major complex public health problems, such as vaccination hesitancy and access to vaccination, requires innovative, open and transdisciplinary approaches. Yet, institutional silos, paywalls and lack of participation of non-academic citizens in the design of solutions hamper efforts to meet these challenges. Against this background, new solutions have been explored, with participatory research, citizen science, hackathon and challenge-based approaches being applied in the context of public health.

Objective:

Our ambition was to develop a framework for creating citizen science and open innovation international projects that address the contemporary challenges of vaccination in France and across the globe.

Methods:

We designed and implemented Co-Immune, a programme created to tackle the question of “vaccination hesitancy” and “access to vaccination” through an online and offline challenge-based open innovation approach. The programme was run on the open science platform Just One Giant Lab.

Results:

Over a 6-month period, the programme mobilized 234 participants of diverse backgrounds, coordinated 8 events, involved 13 partners from the public and private sectors, and led to the creation of 22 projects, from app development and data mining to analysis and game design.

Conclusions:

Co-Immune highlights that open science and open innovation approaches can be facilitated through events and online platforms. They can also help gather and coordinate non-institutional communities in a rapid, distributed and global way to address public health-related issues. Co-Immune contributes to a path for organisations and individuals to collaboratively tackle future global challenges.


 Citation

Please cite as:

Masselot C, Greshake Tzovaras B, Graham C, Finnegan G, Jeyaram R, Vitali I, Landrain T, Santolini M

Implementing the Co-Immune Open Innovation Program to Address Vaccination Hesitancy and Access to Vaccines: Retrospective Study

J Particip Med 2022;14(1):e32125

DOI: 10.2196/32125

PMID: 35060917

PMCID: 8817221

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.